Leave Your Message
Oncology
Oncolytic virus technology for the treatment of melanoma

Oncolytic virus technology for the treatment of melanoma
The world's first CD7 CAR-T therapy

The world's first CD7 CAR-T therapy
Small molecule innovative drug with brain-penetrant-resistant mutant FGFR2/3 inhibitors (novel chemical structure irreversible inhibitors).

Small molecule innovative drug with brain-penetrant-resistant mutant FGFR2/3 inhibitors (novel chemical structure irreversible inhibitors).
High brain-penetrant microtubule stabilizers (MSA)

High brain-penetrant microtubule stabilizers (MSA)
FIC EP2/EP4 dual antagonist

FIC EP2/EP4 dual antagonist
USP1 (Ubiquitin-Specific Peptidase 1) inhibitor

USP1 (Ubiquitin-Specific Peptidase 1) inhibitor
0102030405

Oncolytic virus technology for the treatment of melanoma

2024-07-19
  • Program：Oncolytic virus technology for the treatment of melanoma
  • Indication: Melanoma
  • Status：phase III
  • Collaboration Opportunity: Licensing collaboration/co-development; investment and financing
  • Highlights：
  • The oncolytic virus injection for melanoma treatment has demonstrated significant efficacy and has been recognized by regulatory authorities in both China and the United States.
  • Research and production costs are controllable, with pilot-scale production costs at 100 RMB per dose, and commercial-scale production costs expected to be even lower.
  • The company's candidate drug, oncolytic nanoparticles, which innovatively combine oncolytic viruses with proprietary Nano liposomes, is expected to achieve a breakthrough in systemic administration.